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Mycoplasma gallisepticum is one of the most important pathogens that cause chronic
respiratory disease in chicken. This study investigated the antibacterial activity of
doxycycline against M. gallisepticum strain S6. In static time–killing studies with
constant antibiotic concentrations [0–64 minimum inhibitory concentration (MIC)],
M. gallisepticum colonies were quantified and kill rates were calculated to estimate
the drug effect. The half-life of doxycycline in chicken was 6.51 ± 0.63 h. An
in vitro dynamic model (the drug concentrations are fluctuant) was also established
and two half-lives of 6.51 and 12 h were simulated. The samples were collected
for drug concentration determination and viable counting of M. gallisepticum. In
static time–killing studies, doxycycline produced a maximum antimycoplasmal effect of
5.62log (CFU/mL) reduction and the maximum kill rate was 0.11 h−110 . In the in vitro
dynamic model, doxycycline had a mycoplasmacidal activity in the two regimens, and
the maximum antimycoplasmal effects were 4.1 and 4.75log10 (CFU/mL) reduction,
respectively. Furthermore, the cumulative percentage of time over a 48-h period that
the drug concentration exceeds the MIC (%T > MIC) was the pharmacokinetic–
pharmacodynamic index that best correlated with antimicrobial efficacy (R2 = 0.986,
compared with 0.897 for the peak level divided by the MIC and 0.953 for the area under
the concentration–time curve over 48 h divided by the MIC). The estimated %T > MIC
values for 0log10 (CFU/mL) reduction, 2log10 (CFU/mL) reduction and 3log10 (CFU/mL)
reduction were 32.48, 45.68, and 54.36%, respectively, during 48 h treatment period
of doxycycline. In conclusion, doxycycline shows excellent effectiveness and time-
dependent characteristics against M. gallisepticum strain S6 in vitro. Additionally, these
results will guide optimal dosing strategies of doxycycline in M. gallisepticum infection.
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INTRODUCTION
Mycoplasma gallisepticum belongs to the class Mollicutes, order Mycoplasmatales, family
Mycoplasmataceae which is characterized by lacking a cell wall (Athamna et al., 1997; Uilenberg
et al., 2006). Similar to many other pathogenic mycoplasmas, this microorganism colonizes
its host via the mucosal surface of the respiratory tract and the most paramount process to
develop an infection is the adhesion of M. gallisepticum to its host target cell initially. Besides,
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M. gallisepticum colonizes the respiratory tract usually as a
risk factor for subsequent systemic infection, such as salpingitis
and arthritis (Winner et al., 2000; Nascimento et al., 2005).
This infectious disease spreads vertically through infected eggs
and horizontally by close contact, which result in worldwide
prevalence of M. gallisepticum infection. The disease brings
serious economic loss to farmers. In an earlier published
report, M. gallisepticum infection caused reduction in egg
production, weight gain, and feed conversion efficiency of 10–
20%, and an increase in embryo mortality and chick mortality
of 5–10% (Kleven, 1990). Antimicrobial chemotherapy plays
a significant role in treating infections of M. gallisepticum.
However, mycoplasma has been regarded as a kind of fastidious
and slowly growing microorganism. Mycoplasma requires
appropriate growth media and culturing condition, so research
on mycoplasma is difficult in many instances. Quantitative
cultures have been established with color changing unit (CCU) or
CFU determination by serial dilution and plating on appropriate
agar (Stemke and Robertson, 1982). Even though viable count
estimation is complicated by strict nutritional conditions of
M. gallisepticum cell, the CFU determination is an accurate
measure for quantifying the number of M. gallisepticum clone,
and resistant M. gallisepticum stains could be selected from the
agar plate.
In the past decades, there were a few reports concerning
PK/PD integration of antimicrobials against mycoplasmas.
Mitchell et al. (2012, 2013a,b) have evaluated the antimicrobial
activity against M. mycoides subspecies mycoides Small Colony by
in vitro dilution PK/PD model. Xiao et al. (2015a,b) have studied
the PK/PD relationship of valnemulin against M. gallisepticum by
ex vivo model and in vivo model, with a real-time PCR (RT-PCR)
method to detect M. gallisepticum. However, a more reasonable
model and more accurate viable count estimation should be
applied to explore the relationships between antimicrobials and
mycoplasmas.
A multitude of agents inhibiting protein synthesis have
been demonstrated to be efficacious against M. gallisepticum,
including tetracyclines, macrolides, quinolones, and tiamulin
(Cooper et al., 1993; Bradbury et al., 1994; Gerchman et al.,
2008; Zakeri and Kashefi, 2011). Doxycycline is a semi-synthetic
bacteriostatic tetracycline whose pharmacokinetic property is
superior to older tetracyclines (Soliman et al., 2015). In this study,
the in vitro dynamic model to simulate the pharmacokinetic
profiles of doxycycline in chickens was established on the basis
of the in vitro pharmacokinetic/pharmacodynamic model used
to evaluate the properties of antifungal drugs against Aspergillus
species (Meletiadis et al., 2012). Besides, quantitative culture
was performed by counting colonies on ager plate to investigate
the PK/PD interaction of doxycycline against M. gallisepticum.
Moreover, because the growth characteristic of M. gallisepticum
is significantly different from other microorganisms, the kill
rate was introduced so as to evaluate the pharmacodynamics
of doxycycline in the time–killing study. The purpose of
this study was to characterize the activity of doxycycline
against S6 strain of M. gallisepticum by in vitro static
time–killing studies preliminarily. Then PK–PD index that
best correlated with antimicrobial efficacy was analyzed. The
results of this study could provide guidance for dosing
regimen design in the clinical treatment of M. gallisepticum
infection.
MATERIALS AND METHODS
Materials
The M. gallisepticum standard strain S6 and doxycycline standard
were obtained from China Institute of Veterinary Drugs
Control, Beijing. M. gallisepticum artificial medium base was
purchased from Qingdao Hope Biological Technology. Sterile pig
serum was provided by Guangzhou Ruite Biological Technology.
Nicotinamide adenine dinucleotide (NADH) and cysteine were
purchased from Guangzhou prob information Technology.
Doxycycline powder was supplied by Guangdong Dahuanong
Animal Health Products. Fresh solutions of doxycycline were
prepared in ultrapure water at 3200 mg/L on the day of the
experiment.
Twelve Sanhuang broiler chickens were kindly supplied by
from the Guangdong Academy of Agricultural Sciences. They
were housed in cages and supplied with water ad libitum.
Chickens were fed on a balanced ration free from any antibiotic
drugs before starting experiments to ensure complete clearance of
their bodies from any drug residues. All husbandry practices and
experimental operations were performed with full consideration
of animal welfare. Research ethical approval was granted by the
South China Agriculture University Animal Ethics Committee
(2015-A027).
Determination of Minimum Inhibitory
Concentration (MIC)
Minimum inhibitory concentration of doxycycline against
M. gallisepticum strain S6 was determined by using a modified
MIC assay method, as described by Tanner and Wu (1992).
Briefly, the final concentration of doxycycline ranging from
0.03125 to 16 mg/L in each well and serial twofold dilutions of
doxycycline were performed. The exponential-phase culture was
diluted with medium to the desired inoculum size between 105
and 107 CFU/mL. Serial twofold dilutions of drug were applied,
containing 0.1 mL of each compound dilution and supplemented
with 0.1 mL of M. gallisepticum inoculum from the first to
the ninth column. 0.2 mL of sterile M. gallisepticum broth at
pH 7.8 was added to well number 10, as a sterility control.
Moreover, growth control (M. gallisepticum inoculum in absence
of antimicrobials), end-point control (blank medium at pH 6.8)
were also included. The M. gallisepticum count of the inoculum
must be tested simultaneously with the MIC determination to
confirm the inoculum that ranging from 105 to 107 CFU/mL.
After being sealed with gas permeable film, plates were cultured in
a 37◦C, 5% CO2 humidified incubator. The MIC was determined
as the minimal concentration of doxycycline that resulted in no
change in color. Changes of color were monitored three times
a day until the color of the growth control was same as that
of the end-point control. All experiments were performed in
triplicates.
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Exposure to Constant Antibiotic
Concentrations
Eight clinically achievable concentrations of doxycycline were
used (0, 0.5, 1, 2, 4, 8, 16, 32, and 64 MIC). 0.4 mL of
the suspension in exponential phase was added into a 7-mL
penicillin bottle to obtain the initial titer whose inoculum size
was approximately 107 CFU/mL, each containing 0.1 mL of
drug solution at 40 times the target concentration and 3.5 mL
blank medium. These penicillin bottles were cultured for 48 h
at 37◦C and aliquots of 100 µL of each culture were removed
at 0, 2, 12, 15, 18, 24, 26, 36, 38, and 48 h to characterize
the effect of various concentrations of doxycycline on the total
M. gallisepticum population. Growth control (M. gallisepticum
culture in the absence of antimicrobials) and sterility control
(4 ml of M. gallisepticum medium at the pH 7.8 was added
into the penicillin bottle) were included. The viable counts of
M. gallisepticum were quantified by 10-fold serial dilutions of
the samples, then 10 µl of each M. gallisepticum dilutions (in
triplicate or more for greater accuracy) were transferred to
the surface of M. gallisepticum agar plates which were freshly
prepared and dried. Plates were incubated at least 7 days in a
37◦C, 5% CO2 humidified incubator. The theoretical lower limit
of detection was 100 CFU/mL and time–killing studies were
conducted on different days to ensure reproducibility of the data.
Time–Killing Curve Fitting and Analysis
The change in the kill rate over time has also been described as
the result of drug effects on a heterogeneous population. Once
growth rates reduced, the susceptibility reduced (Nielsen et al.,
2007). Our group has taken the following approach to obtain
the kill rate. Firstly, time–killing curve were depicted by plotting
log10 (CFU/mL) against time (h) with different concentrations
of doxycycline. Additionally, kill rate was reflected by the slope
of the curve at the given time interval (0∼24, 0∼36, 0∼48,
2∼24, 2∼36, 2∼48, and 12∼48 h). As a result, seven kill rates
were obtained from each concentration. Besides, the kill rates
were also calculated from 2 h and 12 h because that delayed
growth of M. gallisepticum was observed by transferring to the
culture vessel. Finally, linear regression was used to calculate
the slope for each time interval, and then the kill rate (the
slop value) and the doxycycline concentrations were fitted to
the Emax model employing WinNonlin (version 6.1, Pharsight
Corporation, Mountain View, Sunnyvale, CA, USA). The Emax
model could be described by the following equation:
E = Emax × C
N
e
ECN50 + CNe
(1)
Where E is the kill rate, Emax is the maximum kill rate in a certain
period of time, Ce is the doxycycline concentration, N is the Hill
coefficient that describes the steepness of the kill rate-effect curve.
EC50 is the doxycycline concentration which produced 50% of the
maximum kill rate. The correlation coefficient R2 represented the
strength and direction of relationship between the experimental
data (observed values) and the Emax model (predicted values) on a
scatterplot. Because the kill rates were obtained from the different
time periods, seven scatterplots could be depicted. The value R2
quantifies goodness of fit, thus the higher values indicated that
the data fits the model better in the corresponding time period.
Pharmacokinetics of Doxycycline in
Chicken
Doxycycline was administered intravenously at a single dose
of 10 mg/kg bodyweight (BW) to 12 broiler chickens. The
mean body weight (±SD) of the chicken was 1.53 ± 0.31 kg.
Blood samples were taken from the left brachial wing vein of
each chicken just before and at 0.08, 0.17, 0.25, 0.5, 1, 2, 4,
6, 8, 10, 12, 24, 36, and 48 h post-antibiotic injection. Blood
samples were centrifuged at 3000 g for 10 min and plasma were
collected and stored at −20◦C until assayed for doxycycline.
The concentration of doxycycline was determined by high-
pressure liquid chromatography–tandem mass spectrometry
HPLC–MS/MS as described elsewhere (Patel et al., 2011). The PK
data of doxycycline were analyzed by WinNonlin software.
Exposure to Changing Antibiotic
Concentrations
The in vitro pharmacodynamic model has been described in
detail previously (Meletiadis et al., 2012). Briefly, a modified
three-necked flask containing 320 mL medium (external
compartment [EC]) could be more conducive to sampling and
also reduce the risk of contamination. Three necks of the
flask served as inlet tubing, sampling tube, and outlet tubing,
respectively. The sampling tube consisted of a rubber stopper, two
elongated syringe needles, and two 0.22-µm nylon filters.
The intravenous formulation and long-acting parenteral
formulation were simulated by two half-lives of doxycycline
which were 6.51 and 12 h. At time zero, doxycycline was
injected into both the EC and the IC (internal compartment)
simultaneously, which resulted in the initial drug concentration
from 1 to 64 MIC of doxycycline. Meanwhile, the IC was
inoculated with 10 mL medium containing approximately
107 CFU/mL of M. gallisepticum. Then the drug-free medium
was pumped continuously into the EC from the reservoir to
dilute the drug, and a second pump guaranteed the discharging.
The drug concentrations conformed to the first order model:
C = C0e−kt, C0 is the initial doxycycline concentration, C
is the doxycycline concentration at time t, k is the rate of
elimination and t is the time that has elapsed since the addition
of doxycycline.
The experiment was conducted for 48 h, the EC was placed
in a water jacket to keep the temperature constant at 37◦C and
a magnetic stirrer was used to keep the media homogeneous.
Samples were collected from the EC (2 mL) and IC (0.1 mL)
simultaneously at 2, 12, 15, 18, 21, 24, 36, and 48 h after injection
during the experiment for drug concentration determination
and viable counting of M. gallisepticum. All experiments were
performed in triplicates.
Pharmacokinetic Analysis
Serial samples were obtained from the EC and stored at
−20◦C until being assayed. The concentration of doxycycline
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was determined by using a previously described method (high-
pressure liquid chromatography–tandem mass spectrometry
HPLC–MS/MS, Agilent Technologies, USA; Tarapoulouzi et al.,
2013). The mobile phase consisted of solution A (water with 0.1%
formic acid, V/V) and solution B (acetonitrile) at 0.25 mL/min
flow rate. The gradient elution was: 0–1 min, 90% A; 1–
4 min, 70% A; 4–5 min, 50% A; 5–13 min, 90% A. The
injection volume was 5 µL. The half-life for each regimens,
area under the concentration versus time curve (AUC0−48 h),
mean residence time, volume of distribution, and total body
clearance of doxycycline were calculated from the concentration–
time plot by using a one-compartment pharmacokinetic model
for intravenous bolus administration. AUC0−48 h was calculated
because the pharmacokinetic parameter values were determined
after a single dose and the period was 48 h.
Pharmacokinetic–Pharmacodynamic
Integration and Modeling
Specific PK/PD indices (T > MIC, Cmax/MIC, AUC0−48 h/MIC)
have been identified which are of major importance for the
assessment of antimicrobial activity against M. gallisepticum,
reducing the emergence of resistance and establishing a rational
dosage regimen. For PK–PD integration, the surrogate indices
were calculated according to a one compartmental analysis by
WinNonlin. The software was employed to fit data to a sigmoid
Emax model which was described by the formula as follows.
E = E0 − Imax × C
N
e
ICN50 + CNe
(2)
Where E is the antimycoplasmal effect, E0 is the change in
log10 (CFU/mL) of control sample (absence of doxycycline)
after 48 h incubation. Imax is the maximum antimycoplasmal
effect determined as log10 (CFU/mL) reduction in samples
incubated with doxycycline between time 0 and 48 h. IC50 is
the drug concentration that gives rise to 50% of the maximum
antimycoplasmal response. Ce is the PK/PD indices (Cmax/MIC,
AUC0−48 h/MIC and T > MIC) in the effect compartment, while
N is the Hill coefficient that describes the steepness of the
PK/PD indices-effect curve and R2 were calculated for each assay.
Values for E between 0 and −3log10 (CFU/mL) reduction were
considered to be of mycoplasmastasis activity, whereas values less
than or equal to −3log10 (CFU/ml) denoted mycoplasmacidal
activity.
RESULTS
Minimum Inhibitory Concentration
The MIC of doxycycline for M. gallisepticum strains S6 was
0.125 mg/L for the three different inoculum sizes (105, 106, and
107 CFU/mL). No growth of M. gallisepticum was observed in the
sterilizing control, end-point control, while growth was observed
in the positive control, and validating the experiments.
Static Time–Killing Curves and Analysis
The results of the static time–killing study are presented as
dots in Figure 1. These doxycycline doses produced marked
reductions in organism burden ranging from 0.84 to 5.62log10
(CFU/mL) reduction with M. gallisepticum, compared with the
starting inoculum. At low concentration of doxycycline (0.5
MIC), M. gallisepticum counts were slight increased by 0.15log10
(CFU/mL). Inhibition of M. gallisepticum growth was observed
in 1∼4 MIC, decreased by 0.84∼2.97log10 (CFU/mL) during
the experimental process. There was mycoplasmacidal activity,
more than 4log10 (CFU/mL) reduction, when M. gallisepticum
was exposed to high concentration of doxycycline at 8∼64
MIC. Actually, the 32 MIC has already achieved the maximal
effect, showing 5.62log10 (CFU/mL) reduction during 48 h.
As the antibiotic concentration increased (0.5∼8 MIC), the
antimycoplasmal activity gradually increased. Nonetheless, there
was no significant difference in the decline number of
M. gallisepticum colonies between 8 and 64 MIC. Overall, the
antimycoplasmal effect appeared not to be always dependent on
concentration.
The relationships between the kill rate and drug concentations
is represented graphically in Figure 2 (the time interval was
0∼48 h). All pharmacodynamic parameters are obtained from the
Emax model with variable slopes and the data was satisfactorily
fitted to the model (the mean R2 was 0.961 ± 0.026). The
maximum R2 for kill rate-concentration curve was 0.986 and the
maximum kill rate was 0.11 h−1 from the period of 0∼48 h.
The kill rate profile of doxycycline against M. gallisepticum
manifested that when the concentration exceeded 8 MIC, the
kill rates seemed to be a plateau after a rapid rise phase. The
results of model analysis also confirmed that the growth rate for
M. gallisepticum was relatively low (0.02 h−1). The relationship
between concentration and kill rate was fitted by Emax model,
and the obtained parameters of Emax, EC50, Hill coefficient are
presented in Table 1.
Pharmacokinetics Analysis in Chicken
The mean plasma concentration–time curve of doxycycline
in chickens are shown in Figure 3. The PK parameters are
FIGURE 1 | Time–killing studies of doxycycline (as multiples of MIC)
against Mycoplasma gallisepticum with constant concentrations. Data
are presented as geometric means based on triplicates.
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FIGURE 2 | The best-fit curve obtained from the Emax model of
M. gallisepticum exposed to doxycycline between 0 and 48 h. R2 is the
correlation coefficient.
TABLE 1 | The kill rate parameter estimation derived from the Emax model
which fitted to in vitro static time–killng assay data.
Time (h) Emax (h−1) EC50 (µg/mL) Hill’s slope R2
0–24 0.12 0.02 1.45 0.958
0–36 0.11 0.38 2.21 0.971
0–48 0.11 0.32 2.11 0.986
2–24 0.1 0.33 2.21 0.955
2–36 0.1 0.32 2.47 0.97
2–48 0.11 0.31 2.83 0.907
12–48 0.12 0.28 2.2 0.977
summarized in Table 2. The half-life was 6.51 ± 0.63 h, mean
residence time was 6.21 ± 0.42 h, volume of distribution was
0.54 ± 0.17 L/kg and total body clearance of doxycycline was
0.06± 0.12 L/h kg. AUC0−24 h was 164.40± 4.78 µg h/mL.
Pharmacokinetics in In Vitro Dynamic
Model
The limit of detection and limit of quantification for the
developed method was 5 and 10 ppb (ng/mL), respectively.
A calibrated curve was constructed by adding a known amount of
doxycycline to blankM. gallisepticum culture over concentrations
ranging from 0.005 to 0.5 µg/mL (R2 > 0.999). The within-
run relative standard deviations (RSDs; n = 6) for doxycycline
quality control concentrations of 0.1, 0.02, and 0.01 µg/mL
were 2.02, 1.43, and 2.37%. The between-run RSDs for the
same quality control concentrations (n = 18) were 2.32,
1.70, and 2.83%. The recoveries of doxycycline in drug-free
medium were 84.54 ± 0.68% (mean ± standard deviation, SD,
n = 6). The time–concentration curves for in vitro dynamic
model are shown in Figure 4. Half-lives were calculated to be
FIGURE 3 | Mean plasma concentration–time profile of doxycycline
following intravenous administration at a single dose of 10 mg/kg BW
to chickens.
6.19 ± 0.43 and 11.93 ± 0.74 h, and mean residence times
were 8.29 ± 0.36 h and 17.03 ± 0.41 h, respectively. Volume
of distribution were 0.90 ± 0.10 and 0.99 ± 0.20 L, and total
body clearance were 0.10 ± 0.01 and 0.06 ± 0.01 L/h, according
to the initial experimental design of 6.51 and 12 h half-life,
respectively.
Dynamic Time–Killing Curves and
Analysis
Figure 5 shows the effect of antibiotic against M. gallisepticum
at different concentrations of two simulated regimens whose
half-lives were 6.51 and 12 h. Escalating doses of doxycycline
resulted in marked killing of M. gallisepticum. Regrowth was
observed in all regimens except one that simulating the C0 of
doxycycline was 64 MIC and half-life was 11.93 h. Doxycycline
was mycoplasmacidal activity in the two regimens whose Imax
were 4.1 and 4.75log10 (CFU/mL) reduction. Since the EC was
continuously diluted by drug-free medium, the curves tended to
gently decline. When the drug concentration dropped below the
MIC, the regrowth of the M. gallisepticum was detected promptly.
On the whole, the Figure 5 illustrated that the potency of
doxycycline with long half-life was superior to the short half-life.
TABLE 2 | Pharmacokinetic parameters of doxycycline in plasma following
intravenous administration at a single dose of 10 mg/kg BW to 12
chickens.
Parameters (units) Mean ± standard deviations (SD)
AUC0−24 h (µg h/mL) 164.40 ± 4.78
MRT (h) 6.21 ± 0.42
CL (L/h·kg) 0.06 ± 0.12
V (L/kg) 0.54 ± 0.17
T1/2(h) 6.51 ± 0.63
AUC0−24 h, 24 h area under plasma concentration–time curve; MRT, mean
residence time; CL, total body clearance; V, volume of distribution; T1/2, elimination
half-life.
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Pharmacokinetic–Pharmacodynamic
Modeling and Analysis
The PK/PD parameters (AUC0−48 h/MIC; Cmax/MIC; T > MIC)
derived from dynamic time–killing assays and antimycoplasmal
effect are expatiated in Figure 6. The strongest relationship
was observed when antimicrobial effect was correlated with
the %T > MIC, with an R2 value of 0.989 (AUC0−48 h/MIC
R2 = 0.953; Cmax/MIC R2 = 0.897). The above studies indicated
that antimycoplasmal activity depended on the percentage of
time above the MIC and suggested that efficacy was driven by
the %T >MIC parameter. The relationship between antibacterial
efficacy and the PK/PD parameters was assessed by using the
sigmoid Emax model, and the obtained parameters of E0, Imax,
and IC50, and the Hill coefficient are presented in Table 3. The
estimated %T > MIC values for 0log10 (CFU/mL) reduction,
2log10 (CFU/mL) reduction and 3log10 (CFU/mL) reduction
were 32.48, 45.68, and 54.36%, respectively, during 48 h treatment
period of doxycycline.
DISCUSSION
Mycoplasma gallisepticum is one of the most economically
significant pathogens of poultry, and has a world-wide
distribution. In common with other mycoplasmas,
M. gallisepticum is the smallest known self-replicating organism
and lacks a cell. These characteristics of mycoplasmas were
also reflected in a high degree of interdependence between
mycoplasmas and the host animal, and in the fastidious nature of
the organism in vitro (Levisohn and Kleven, 2000). So far, there
is limited information available on the PK/PD interactions of
antibacterial agents against mycoplasmas. Mitchell et al. (2013b)
have evaluated the antimicrobial activity against M. mycoides
subspecies mycoides Small Colony in in vitro dilution PK/PD
model. They have evaluated a series of antimicrobials activity
in vitro, but in the in vitro model, the dilution was simulated
by increasing volume. A continuous dilution and an outlet
to mimic elimination of drug have not been offered by this
model. Whereas our dynamic model not only provided the
continuous flow without increasing volume, but also eliminated
the agent through an outlet; Xiao et al. (2015a,b) have studied
the PK/PD relationship of valnemulin against M. gallisepticum
by ex vivo model and in vivo model with the target species.
The dosage regimen for valnemulin against M. gallisepticum
based on PK/PD modeling and a real-time PCR (RT-PCR)
method quantitative detection of M. gallisepticum were provided.
However, it is difficult for CCU method to quantitate the
number of M. gallisepticum accurately, for the reason that
M. gallisepticum belongs to the slow growing microorganism.
The results can only be recorded at least 7 days later until the
color changed from red to orange or yellow, while the color of
liquid medium may also be changed by acidification of carbon
dioxide over time, which may lead to some confusion. Although
the RT-PCR methodology gave result quickly and specifically,
this detection method was performed indirectly and may be
impeded by other organisms or dead subculture. The CFU
quantitative detection adopted by us in this study is accurate
because the M. gallisepticum colony is recorded from inverted
microscope directly and the resistant mutant could be selected
from the agar plate. Arai et al. (1993) have studied various agents
and treatment regimens for experimental M. pneumonia. The
rat infection model was utilized, and CFU of M. pneumonia
in lung and bronchoalveolar lavage samples were quantitated
as well (Ishida et al., 1994; Kaku et al., 1994). Nevertheless,
the drug concentrations and log10 (CFU/mL) reduction have
not been fitted by PK/PD modeling that could provide a
foundation for the application of antibacterial agents against
M. pneumonia infections. In addition, in the two aforementioned
in vivo models, changes in the amount of bacteria during the
experiment were not recorded continuously, while continuous
colony counting was performed in our dynamic in vitro model.
In this study, we strived to investigate the PK/PD interactions
of doxycycline against M. gallisepticum in in vitro model.
Available information was provided by our results, which
could be used to support dose selection in a more rational
manner.
The MIC of doxycycline against M. gallisepticum strain S6 was
0.125 mg/L. In the determination of MIC, the final inoculum
size of M. gallisepticum in each well was between 105 and
107 CFU/mL. Although the recommended turbidity of MIC
testing against veterinary mycoplasma species was between 103
and 105 CFU/mL (Hannan, 2000), the turbidity of the growth
phase of the mycoplasmas seemed less important (Whithear
et al., 1983). The inoculum size was replaced by current
method and the same results were obtained for the inoculum
size between 105 and 107 CFU/mL. There were two primary
reasons for choosing the high inoculum. First, the population
of M. gallisepticum was consistent with the in vitro dynamic
experiment where the initial inoculum was approximately
107 CFU/mL. Second, the high inoculum was applied to simulate
the M. gallisepticum density in severe infection, and may allow
a resistant subpopulation(s) to be present, as the real situation
in infection site. Furthermore, the MIC of doxycycline against
M. gallisepticum strain S6 was similar to the previous report in
which the final concentration of the M. gallisepticum organisms
was approximately 104 CFU/ml (Pakpinyo and Sasipreeyajan,
2007).
It has been reported that oxytetracycline lacked
mycoplasmacidal activity against clinical strains of M. mycoides
subspecies mycoides Small Colony when the assays were
conducted for 12 and 24 h under constant concentration
(Mitchell et al., 2012, 2013b). However, the present study showed
that the M. gallisepticum achieved mycoplasmacidal activity
against M. gallisepticum after 48 h exposure. One explanation
may be that a delay in the growth of M. gallisepticum was
observed, possibly related to the fact that M. gallisepticum
was not instantaneously in their logarithmic growth phase
when transferred to the culture vessel. Another may be that
doxycycline is a slow-acting bacteriostatic agent and associated
with reversible inhibition of protein synthesis. So it may be more
reasonable to study the antimycoplasmal activity in a longer time
periods (48 h).
One novel, crucial step for the kinetic model is the
establishment of Emax model between kill rate and antimicrobial
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FIGURE 4 | Concentration–time curves of doxycycline in the in vitro dynamic model simulating two half-lives of 6.51 h (A) and 12 h (B).
FIGURE 5 | Dynamic time–killing curves were depicted at different concentrations of doxycycline for the two simulated regimens. The mean half-lives
were 6.19 ± 0.43 h and (A) and 11.93 ± 0.74 h (B). Data points represent geometric means of three experiments.
agent concentration. In some cases, only the initial slope of
the killing curves were employed for the pharmacodynamic
parameters (Regoes et al., 2004; Mouton and Vinks, 2005;
Treyaprasert et al., 2007). Although this approach is propitious
to microorganism that grow quickly, it seemed to be inaccurate
when the initial slope is not log-linear. However, our results
illustrated that the M. gallisepticum grew slowly and the
growth rate was 0.02 h−1. Accordingly, in our study, it was
improper to estimate the pharmacodynamic parameters with
the initial slope. In this study, WinNonlin was employed to
fit the drug concentration and the kill rate (obtained from
different intervals). There was no significant difference in the
estimated R2 value from the different intervals, and the maximum
R2 value came from the longest time period 0∼48 h which
was our experimental cycle. It was desirable to estimate the
overall effect of antibiotic agent on M. gallisepticum through
the longest observation period. Furthermore, for the purpose
of assessing the killing profiles in different concentration, we
modeled the experimental data mathematically by kill rate to
provide an objective and quantitative evaluation. The kill rate
of drug was influenced by time exposed to the microorganism
or the various concentrations of drug. Hence the kill rate
was divided into time-dependent and concentration-dependent
(Craig, 2002). Figure 2 suggested that the kill rate was
time-dependent effect because the kill rate remained constant
when the concentration exceeded 8 MIC. Some investigators
argue that time-dependent drugs do not lead to faster killing,
whereas concentration-dependent drugs do when the antibiotic
concentration exceeded 4 MIC. However, others asserted that,
based on visual inspection of killing curve data, it was
controversial that the threshold value was 4 MIC (Craig, 1998;
Ambrose, 2007).
Our research suggested that doxycycline exhibited time-
dependent killing in in vitro model. In the past decades, there is
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FIGURE 6 | Emax relationships for the three PK/PD parameters versus antimycoplasmal effect. (A) AUC0−48 h/MIC-antimycoplasmal effect curve; (B)
Cmax/MIC- antimycoplasmal effect curve; (C) T > MIC-antimycoplasmal effect curve. R2 is the correlation coefficient.
only one study that identified PK/PD index of doxycycline. The
result has showed that doxycycline was time-dependent kinetic
at low serum concentrations but concentration-dependent
kinetic at high serum concentrations against Escherichia coli,
Staphylococcus aureus, Pasteurella multocida, and Streptococcus
pneumoniae (Cunha et al., 2000). However, our results showed
that doxycycline was time-dependent characteristics against
M. gallisepticum, and this difference may be caused by
different target microorganism. This phenomenon had once
been officially reported by other people (Tam et al., 2006),
one of his study found that gentamicin exhibited time-
dependent killing profiles against Staphylococcus aureus but
concentration-dependent killing profiles against Pseudomonas
aeruginosa.
In in vitro model, it is possible to have full control of the
drug profile within the system and samples could be continuously
collected to monitor the growth and dying behavior of the
bacteria. The PK/PD relationship represents a key link between
optimal drug dosing and clinical outcomes, which is crucial to
optimize animal outcomes and reduce the risk of resistance.
TABLE 3 | The PK/PD Parameter estimation, and the data are derived from Emax model.
PK/PD parameter Imax ( log10 CFU/mL) IC50 (µg/mL) E0 (log10 CFU/mL) Hill’s slope R2
AUC0−48 h/MIC (h) 5.82 79.12 2.30 0.55 0.953
Cmax/MIC 6.49 10.90 2.28 0.44 0.897
T > MIC (%) 5.93 44.39 2.25 1.12 0.989
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Since the drug concentrations in time–killing studies were
constant over time, the clinical relevance of the results might
not be very evident. Therefore, an in vitro dynamic infection
model was expected to provide further clinical insights. The
model was developed by Meletiadis et al. (2012) and it was
soon be used in additional studies by the same research group
(Al-Saigh et al., 2012, 2013). The merits of the dialysis-tube
infection model were extensive. For instance, a steady state
of nutrient and M. gallisepticum were obtained in these open
systems, without the bacteria loss and penetrating into the
reservoir, which could falsifies the results. Moreover, the in vitro
dynamic model was modified and showed great advantage over
the other in vitro PK–PD models for M. gallisepticum, as it
considered the sterile environment and special needs of the
investigation. Figure 5 showed that better antimycoplasmal effect
was attained with the longer half-life. The explanation might be
that the drug concentration decreased more slowly, leading to
a longer lasting effect with the half-life of 12 h. The regrowth
of M. gallisepticum was observed in the dynamic model. Two
main empirical points of view were speculated for the mechanism
of regrowth. Primarily, the total M. gallisepticum population
consisted of a few distinct and discrete M. gallisepticum
populations, and the preexisting resistant subpopulation may
be selected to prosper and replaced the entire population when
challenged with an antibiotic. Consequently, regrowth and the
emergence of resistance as a gradual process evolved over
time. In addition, the regrowth of M. gallisepticum after initial
decline of the mycoplasma population was due to an adaptation
response.
With constant concentrations, doxycycline produced a
maximum antimycoplasmal effect of 5.62log10 (CFU/mL)
reduction. Moreover, kill rate studies not only provided accurate
characterization of the effect of doxycycline than MIC alone, but
also validated the time-dependent antimycoplasmal activity of
doxycycline. The relationship between doxycycline concentration
and kill rate was time-dependent characteristics and the
maximum kill rate was 0.11 h−1. The in vitro dynamic time–
killing assays also demonstrate that antimycoplasmal activity
of doxycycline against M. gallisepticum was time-dependent
characteristics and PK–PD parameters should be based on
the %T > MIC (R2 = 0.986). However, time-dependent
characteristics needs to be confirmed by further studies such as
in vivo PK/PD model and fractionation schedules. These in vitro
models will provide practical data that are much closer to the
in vivo situation and may aid in the design of more reasonable
treatment regimens.
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